Biorelevant drug release of Metformin dosage forms using complementary in vitro tools

Abstract

Drug release from immediate release (IR) and extended release (ER) metformin products was investigated using the Dow Chemical Company’s FloVitroTM biorelevant dissolution instrument. This was complemented by using the Sirius SDi2 (Surface Dissolution Imaging) platform to investigate mechanistic differences accounting for drug release. Level A IVIVC was demonstrated for metformin IR dosage forms, using FloVitroTM, whilst ER tablets demonstrated lower Cmax and Tmax using the same method. The SDi2 showed disintegration as the main release mechanism for IR tablets, whilst swelling and drug diffusion was observed for ER tablets. FloVitroTM and SDi2 technologies can be used to compare behaviour of formulations during dosage form selection

Keywords

Medicine, pharmacy, Level-A IVIVC, biorelevant dissolution, surface dissolution imaging, IR/ER dosage forms

How to Cite

Box K. , O'Dwyer P. & Watson H. (2017) “Biorelevant drug release of Metformin dosage forms using complementary in vitro tools”, British Journal of Pharmacy. 2(2). doi: https://doi.org/10.5920/bjpharm.2017.15

95

Views

37

Downloads

Authors

Karl Box
Patrick O'Dwyer

Hayley Watson

Download

Dates

Licence

Creative Commons Attribution 4.0

Peer Review

This article has been peer reviewed.

File Checksums (MD5)

  • : b16e919e6cdc64d89d0629095a64f720